Recommendations on Public Health Management of Invasive Group A Streptococcal (iGAS) Disease

Provincial Infectious Diseases Advisory Committee (PIDAC)

September 2014
Public Health Ontario

Public Health Ontario is a Crown corporation dedicated to protecting and promoting the health of all Ontarians and reducing inequities in health. Public Health Ontario links public health practitioners, frontline health workers and researchers to the best scientific intelligence and knowledge from around the world.

Public Health Ontario provides expert scientific and technical support to government, local public health units and health care providers relating to the following:

- communicable and infectious diseases
- infection prevention and control
- environmental and occupational health
- emergency preparedness
- health promotion, chronic disease and injury prevention
- public health laboratory services

Public Health Ontario's work also includes surveillance, epidemiology, research, professional development and knowledge services. For more information, visit www.publichealthontario.ca

The Provincial Infectious Diseases Advisory Committee on Communicable Diseases (PIDAC-CD) is a multidisciplinary committee of health care professionals with expertise and experience in communicable diseases. PIDAC-CD provides advice to Public Health Ontario on communicable disease issues in Ontario, taking into account a focus on those activities where the impact on the community extends beyond the hospital and long-term care home, such as community settings outside of the health sector (e.g., schools and day nurseries), retirement homes and others as appropriate.

Disclaimer for Best Practice Documents

This document was developed by the Provincial Infectious Diseases Advisory Committee on Communicable Diseases (PIDAC-CD). PIDAC-CD is a multidisciplinary scientific advisory body that provides evidence-based advice to Public Health Ontario regarding multiple aspects of infectious disease identification, prevention and control. PIDAC-CD’s work is guided by the best available evidence and updated as required. Best Practice documents and tools produced by PIDAC-CD reflect consensus positions on what the committee deems prudent practice and are made available as a resource to public health and health care providers.

Public Health Ontario assumes no responsibility for the results of the use of this document by anyone.

This document may be reproduced without permission for non-commercial purposes only and provided that appropriate credit is given to Public Health Ontario. No changes and/or modifications can be made to this document without explicit written permission from Public Health Ontario.

Suggested Citation


Public Health Ontario acknowledges the financial support of the Ontario Government.
About This Document

These recommendations were developed for Ontario public health practitioners and health care professionals who are involved in the case and contact management of invasive Group A Streptococcal disease. These recommendations should serve as a companion resource to the following documents, upon which they build:

- **The Ontario Public Health Standards, Infectious Diseases Protocol, 2013, Group A Streptococcal Disease, Invasive (iGAS) chapter, Appendices A and B,**¹² or as current (available at [http://www.health.gov.on.ca/english/providers/program/pubhealth/oph_standards/ophs/infdispro.html](http://www.health.gov.on.ca/english/providers/program/pubhealth/oph_standards/ophs/infdispro.html))


Evidence for Recommendations

The principles and practices recommended in this document are a synthesis of the best available scientific evidence and expert opinion of professionals from the fields of infectious diseases, infection prevention and control, public health and epidemiology. As new evidence arises, these recommendations will be updated as required.

**NOTES:** This document provides recommendations for consideration and reflects currently available evidence and expert opinion for public health management of invasive Group A Streptococcus disease. Health units and health care settings are encouraged to work toward applying these recommendations.

Provincial Infectious Diseases Advisory Committee (PIDAC)

**Public Health Ontario**
[www.publichealthontario.ca](http://www.publichealthontario.ca)
Tel: 647-260-7100  Email: pidac@oahpp.ca

All or part of this report may be reproduced for educational purposes only without permission.
© Queen’s Printer for Ontario, 2014

PIDAC-CD would like to acknowledge the contribution and expertise of the following members and individuals who participated in the development of this document:

**PIDAC-CD Members**

Dr. Eileen de Villa, Chair  
Associate Medical Officer of Health  
Peel Public Health

Dr. Ian Kitai  
Consulting Physician, Infectious Diseases  
Hospital for Sick Children

Dr. Carrie Bernard  
Community Scholarship Lead and Assistant Clinical Professor, Department of Family Medicine  
McMaster University

Heidi Pitfield  
Infection Prevention and Control Coordinator  
Communicable Disease Team  
Simcoe Muskoka District Health Unit

Dr. Margaret Fearon  
Executive Medical Director, Medical Microbiology  
Canadian Blood Services

Lee Sieswerda  
Epidemiologist  
Thunder Bay District Health Unit

Dr. Martha Fulford  
Division of Infectious Diseases  
McMaster University Medical Centre

Dr. Scott Weese  
Associate Professor, Department of Pathobiology  
University of Guelph

Dr. Gary Garber  
Head, Division of Infectious Diseases  
The Ottawa Hospital

Dr. Barbara Yaffe  
Director, Communicable Disease Control  
Associate Medical Officer of Health  
Toronto Public Health

Heather Hague  
Manager, Infectious Diseases Program  
Niagara Region Public Health Department

**Ex-officio Members**

Dr. Catherine Filejski  
Veterinary Consultant  
Infectious Diseases Policy and Programs  
Ministry of Health and Long-Term Care

Dr. Doug Sider  
Medical Director  
Communicable Diseases  
Public Health Ontario

Dr. Colin Lee  
Scientific Lead and Public Health Physician  
Public Health Ontario

Dr. Lillian Wong  
Senior Medical Consultant Network Coordinator  
Occupational Health and Safety Branch  
Ontario Ministry of Labour

**Public Health Ontario Staff**

Naideen Bailey  
Network Coordinator  
Waterloo Wellington Infection Control Network

Dr. Frances Jamieson  
Medical Microbiologist  
Public Health Ontario Laboratories

Maurice Coppin  
Communicable Disease Consultant  
Communicable Diseases

Dr. Liane Macdonald  
Public Health Physician  
Communicable and Infectious Diseases

Claudine D’Souza  
Nurse Consultant  
Communicable Diseases

Emily Karas  
Manager  
Communicable Diseases


Recommendations on Public Health Management of Invasive Group A Streptococcal (iGAS) Disease (September 2014) | ii
# Table of Contents

**Executive Summary** ................................................................. 1

Evidence of severity ................................................................................. 1
Contact management ............................................................................... 1
Screening in long-term care facilities .................................................. 2

**Introduction** .................................................................................... 3

Purpose .................................................................................................. 3
   Evidence of severity ........................................................................ 3
   Contact management ...................................................................... 3
   Screening in long-term care facilities ............................................. 3

**Evidence Review and Expert Consultation** ...................................... 4

Objectives ............................................................................................ 4
Methodology ......................................................................................... 4
   Literature search ........................................................................... 4

**Recommendations** .......................................................................... 7

Evidence of Severity ............................................................................. 7
   1. Determination of the cause of death in an iGAS case for the purposes of chemoprophylaxis ................. 7
   2. Utility of pneumonia as a sole indicator of severity ............................................................................... 8
   3. Definition of soft-tissue necrosis as an indicator of severity ................................................................. 9

Contact Management ........................................................................... 9
   4. Definition of close contacts ........................................................ 9
   5. Duration of monitoring of close contacts of an iGAS case for signs and symptoms of GAS infection: 21 versus 30 days ................................................................. 11

Screening in Long-Term Care Facilities ................................................ 12
   6. Indications for screening in long-term care facilities for GAS ............................................................. 12

**Appendices** .................................................................................... 14

Appendix 1: Jurisdictional comparison of recommendations for chemoprophylaxis .................................. 14
Appendix 2: Jurisdictional comparison of management guidance related to iGAS and death ..................... 155
Appendix 3: Jurisdictional comparison of guidance related to iGAS and pneumonia .................................. 16
Appendix 4: Jurisdictional comparison of the definition of close contacts ................................................. 17
Appendix 5: iGAS case definitions from the PHAC guidelines ................................................................. 18
Appendix 6: Search strategies ............................................................... 19
   Search Strategies ............................................................................ 19
   iGAS infection and close contacts peer-reviewed literature search .......................................................... 19
   iGAS infection and definition of close contacts web/grey literature search ........................................... 21
   iGAS guidelines peer-reviewed literature search ...................................................................................... 23
   iGAS guidelines grey literature (Google) ................................................................................................. 24
Streptococcus pyogenes and transmission peer review literature .................................................................27
iGAS outbreaks in hospitals/long-term care facilities peer reviewed ......................................................29
References..................................................................................................................................................31
Executive Summary

Provincial Infectious Diseases Advisory Committee on Communicable Diseases (PIDAC-CD) developed these recommendations for consideration in response to inquiries from Ontario local public health units about the public health management of invasive Group A Streptococcal (iGAS) disease. These recommendations should serve as a companion resource to the following documents, upon which they build:

- The Ontario Public Health Standards, Infectious Diseases Protocol, 2013, Group A Streptococcal Disease, Invasive (iGAS) chapter, Appendices A and B,¹,² or as current (available at http://www.health.gov.on.ca/english/providers/program/pubhealth/oph_standards/ophs/infdispro.html)

- The 2006 Public Health Agency of Canada Canada Communicable Disease Report supplement Guidelines for the Prevention and Control of Invasive Group A Streptococcal Disease,³ or as current (available at http://www.phac-aspc.gc.ca/publicat/ccdr-rmtc/06pdf/32s2_e.pdf)

PIDAC-CD’s recommendations, which are informed by the best available evidence and expert opinion, pertain to six public health management issues for iGAS disease. In summary, PIDAC-CD recommends the following:

Evidence of severity

1. For the purpose of public health management (i.e., to inform chemoprophylaxis for eligible close contacts), a determination of whether or not iGAS disease was a cause of death should be made only if an iGAS case dies within 7 days of diagnosis.
2. For the purpose of public health management of iGAS disease, GAS pneumonia should not be used as a sole indicator of severity.
3. For the purpose of public health management of iGAS disease, the definition of soft-tissue necrosis should not include superficial or chronic soft-tissue necrosis/gangrene, or acute or chronic cellulitis. Soft-tissue necrosis should be acute in nature and deeper than the skin (e.g., necrotizing fasciitis, myositis and gangrene), as determined by the clinician.

Contact management

4. The Public Health Agency of Canada guidelines’ definition of close contacts should be used to identify groups eligible for chemoprophylaxis,³ i.e., persons exposed to a confirmed severe iGAS case in the 7 days prior to onset of symptoms in the case or up to 24 hours after the case’s initiation of antimicrobial therapy and:
   - Spent 4 hours/day on average in the previous 7 days, OR 20 hours/week with the case, or
   - Shared the same bed or had sexual relations with the case, or
   - Had direct mucous membrane contact with oral or nasal secretions of the case or unprotected direct contact with an open skin lesion of the case, or
   - Shared needles (i.e., for injection drug use) with the case, or
   - In certain circumstances, selected child care and hospital contacts.
If numerous groups of people are identified as eligible for chemoprophylaxis, public health practitioners could give first priority to the timely administration of antibiotic prophylaxis to close contacts in high-risk groups as outlined in the U.S. Centers for Disease Control and Prevention iGAS management guideline (e.g., persons over 65 years, and those with HIV infection, diabetes, chickenpox, cancer, heart disease, injection drug use or steroid use).\(^4\)\(^{p.952}\)

5. Public health units’ advice to close contacts on monitoring for signs and symptoms of iGAS should be consistent with the Public Health Agency of Canada guidelines’ recommendation to “seek medical attention immediately should they develop febrile illness or any other clinical manifestation of GAS infection within 30 days of diagnosis in the index case.”\(^3\)\(^{p.4}\)

**Screening in long-term care facilities**

6. Public health units and health care providers should follow the Public Health Agency of Canada (PHAC) guidelines for screening in long-term care facilities (LTCFs) for GAS to avoid unnecessary screening/rescreening.\(^3\) As per the PHAC guidelines,\(^3\) if a confirmed case of invasive GAS disease is identified in a LTCF, conduct a retrospective chart review to identify an excess of confirmed or suggested GAS among residents in the preceding 4 to 6 weeks. If an excess of GAS infection is identified (as below), consider screening for GAS (i.e., throat, nose and skin lesion cultures) in:

- All patient care staff, and non-patient care staff with a positive history of suggested recent GAS infections and
- All residents in LTCF with < 100 beds, OR, residents in the same unit as the iGAS case and
- Contacts of that case if necessary in LTCF with ≥ 100 beds, OR residents in the same unit as the iGAS case and contacts of that case if necessary, OR more broadly as suggested by resident or staff movements or epidemiologic evidence.

The PHAC guidelines defines an excess of GAS infection in a LTCF as:\(^3\)\(^{p.4}\)

- > 1 case of culture-confirmed iGAS per 100 residents per month, or
- ≥ 2 cases of culture-confirmed iGAS per month in facilities with <200 residents, or
- > 4 cases of suggested invasive or non-invasive GAS per 100 residents per month.
Introduction

Purpose

Provincial Infectious Diseases Advisory Committee on Communicable Diseases (PIDAC-CD) has provided these recommendations for consideration in response to inquiries from Ontario local public health units about the public health management of invasive Group A Streptococcal (iGAS) disease. Specifically, the recommendations provide clarification on the following:

Evidence of severity

1. Determination of the cause of death in an iGAS case for the purposes of chemoprophylaxis
2. Utility of pneumonia as a sole indicator of severity
3. Definition of soft-tissue necrosis as an indicator of severity

Contact management

4. Definition of close contacts
5. Duration of monitoring of close contacts of an iGAS case for signs and symptoms of GAS infection: 21 versus 30 days

Screening in long-term care facilities

6. Indications for screening in long-term care facilities (LTCFs) for GAS
Evidence Review and Expert Consultation

Objectives

To identify and review relevant peer-reviewed and grey literature that addressed the six iGAS public health management issues that were the focus of these PIDAC-CD recommendations (see Purpose).

To obtain and consider expert opinion to supplement gaps in existing evidence on the six iGAS public health management issues that were the focus of these PIDAC-CD recommendations (see Purpose).

Methodology

Literature search

With guidance from PIDAC-CD and Public Health Ontario Communicable Diseases staff, Public Health Ontario Library Services conducted focused literature searches for relevant peer-reviewed and grey literature published between January 1998 and March 2012. An updated literature search (see below) conducted in April and May 2013 yielded no new relevant results.

Peer-reviewed literature search strategy

Electronic health databases were searched for peer-reviewed literature on key concepts (see Tables 1 and 2). Search strategies for each database were constructed using MeSH subject headings and keywords combined with Boolean operators. Only English-language documents were examined. Subject headings and keywords are summarized in Table 1. Databases and publication date limits used for focused searches are summarized in Table 2. Additional details on the search strategy and results are available here: https://secure.publichealthontario.ca/en/BrowseByTopic/InfectiousDiseases/PIDAC/Pages/iGAS_Evidence_Review_Expert_Consultation_and_Search_Strategies.aspx

Grey literature search

Searches of the peer-reviewed literature did not produce a high yield of relevant results. As such, a web search was performed using Google to identify relevant grey literature. The websites of major public health agencies were the focus of the search, such as www.phac-aspc.gc.ca and www.cdc.gov. The websites of all Canadian provincial and territorial health ministries were searched, as well as those of international and national organizations. Additionally, a Google search was performed, limiting the results to .gov, .org, and .edu domains. Reference lists in highly relevant grey literature were also examined. Additional details on the search strategy and results are available here: https://secure.publichealthontario.ca/en/BrowseByTopic/InfectiousDiseases/PIDAC/Pages/iGAS_Evidence_Review_Expert_Consultation_and_Search_Strategies.aspx
Table 1: Key concepts and corresponding MeSH subject headings and keywords-peer-reviewed literature search

<table>
<thead>
<tr>
<th>iGAS</th>
<th>Close contacts</th>
<th>Outbreak/transmission</th>
<th>Hospital/LTCF</th>
<th>Guidelines</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Streptococcus pyogenes/</td>
<td>cross infection/</td>
<td>disease transmission, infectious/</td>
<td>hospital infection/</td>
<td>Not applicable</td>
</tr>
<tr>
<td>Streptococcus Group A/</td>
<td>disease transmission/</td>
<td>infectious disease transmission, professional-to-patient/</td>
<td>long-term acute care hospital/</td>
<td></td>
</tr>
<tr>
<td>Group A Streptococcus</td>
<td>family/</td>
<td>infectious disease transmission, patient-to-professional/</td>
<td>health facilities/</td>
<td></td>
</tr>
<tr>
<td>infections/ adj2 invasive</td>
<td></td>
<td>infectious disease transmission, vertical/</td>
<td>long-term care/</td>
<td></td>
</tr>
<tr>
<td>Group A Streptococcal infection/</td>
<td></td>
<td>cross infection/</td>
<td>health care facility/</td>
<td></td>
</tr>
<tr>
<td>Streptococcus infection/</td>
<td></td>
<td>infection control/</td>
<td>hospital/</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Keywords</th>
</tr>
</thead>
<tbody>
<tr>
<td>• streptococcal disease</td>
</tr>
<tr>
<td>• iGAS</td>
</tr>
<tr>
<td>• streptococcal infections</td>
</tr>
<tr>
<td>• case-patient &quot;person to person&quot;</td>
</tr>
<tr>
<td>• intra-familial</td>
</tr>
<tr>
<td>• close contact</td>
</tr>
<tr>
<td>• carriage</td>
</tr>
<tr>
<td>• shared environment</td>
</tr>
<tr>
<td>• person to person</td>
</tr>
<tr>
<td>• familial carriage</td>
</tr>
<tr>
<td>• intimate contact</td>
</tr>
<tr>
<td>• outbreak</td>
</tr>
<tr>
<td>• disease transmission</td>
</tr>
</tbody>
</table>

Not applicable
Guideline recommend

iGAS, invasive Group A Streptococcal disease; LTCF, long-term care facility.
Table 2: Databases and publication date limits—peer-reviewed literature search

<table>
<thead>
<tr>
<th>Focused search topic</th>
<th>Databases and publication date limits</th>
</tr>
</thead>
<tbody>
<tr>
<td>iGAS infection and close contacts</td>
<td>CINAHL with Full Text, MEDLINE, Academic Search Premier, Nursing &amp; Allied Health Collection, Comprehensive: 2002–2013</td>
</tr>
<tr>
<td>Definition of close contacts</td>
<td>CINAHL with Full Text, MEDLINE, Academic Search Premier, Nursing &amp; Allied Health Collection, Comprehensive: 2002–2013</td>
</tr>
<tr>
<td>iGAS outbreaks in hospitals/long-term care facilities</td>
<td>MEDLINE, Embase: 2002–2013</td>
</tr>
<tr>
<td><em>Streptococcus pyogenes</em> and transmission</td>
<td>MEDLINE, Embase: 2002–2013</td>
</tr>
<tr>
<td>iGAS guidelines</td>
<td>MEDLINE, Embase: 1998–2013</td>
</tr>
</tbody>
</table>

*iGAS, invasive Group A Streptococcal disease.*

**Review of evidence**

Literature search results (e.g., title and abstract) were reviewed for relevance by Public Health Ontario Library Services and Communicable Diseases staff. Peer-reviewed and grey literature that addressed at least one of the six specific iGAS public health management issues under consideration (see Purpose) was included. Studies addressing interventions in settings beyond the scope of these recommendations (e.g., acute care hospitals and child care centers) were excluded from the review.

Using guidelines identified via the grey literature search, jurisdictional comparisons of guidance on public health management of iGAS from public health organizations in Canada, the United Kingdom, the United States, Australia and Ireland were prepared (see Appendices 1 to 4 for a summary of findings of the jurisdictional comparisons).

PIDAC-CD members reviewed the most relevant evidence (i.e., peer-reviewed review articles and single studies, and the jurisdictional comparisons of public health management) via iterative critical discussion at multiple PIDAC-CD meetings about the quality and applicability of the evidence to the public health management of iGAS in Ontario.

**Expert consultation**

PIDAC-CD consulted Dr. Allison McGeer, Microbiologist and Infectious Disease Consultant, Mount Sinai Hospital, Toronto, and Professor, Department of Laboratory Medicine and Pathobiology and Dalla Lana School of Public Health, University of Toronto. In addition, on behalf of PIDAC-CD, PHO staff consulted with Dr. Theresa Lamagni, Epidemiologist, Health Protection Agency, UK (now Public Health England), for expert input in respect of time from iGAS diagnosis to death for surveillance purposes, management of iGAS outbreaks in long-term care facilities, and duration of monitoring for signs and symptoms recommended to contacts of iGAS cases. In addition, PIDAC-CD communicated with other external international experts (i.e., at the Centers for Disease Control and Prevention [CDC] in the United States; and the Queensland Government in Australia) to inform the jurisdictional comparisons. PIDAC-CD also considered this expert opinion via iterative discussion at multiple PIDAC-CD meetings.
Recommendations

Evidence of Severity

The Public Health Agency of Canada (PHAC) guidelines recommend chemoprophylaxis for close contacts of an iGAS case that is “severe,” as per the PHAC iGAS case definitions (see Appendix 5). The following three recommendations provide additional guidance on obtaining and interpreting evidence of severity for the purposes of public health management (i.e., chemoprophylaxis of close contacts of severe iGAS cases). The iGAS disease-specific chapter of the Ministry of Health and Long term Care Ontario Public Health Standards Infectious Diseases Protocol Appendices A and B align with these PHAC recommendations.

1. Determination of the cause of death in an iGAS case for the purposes of chemoprophylaxis

Recommendation

For the purpose of public health management (i.e., to inform chemoprophylaxis for eligible close contacts), a determination of whether or not iGAS disease was a cause of death should be made only if an iGAS case dies within 7 days of diagnosis.

Background

The PHAC guidelines’ definition of a severe iGAS case includes “a confirmed case resulting in death.” As noted above, the PHAC guidelines also recommend chemoprophylaxis of close contacts of a severe iGAS case. The iGAS disease-specific chapter of the Ontario Public Health Standards Infectious Diseases Protocol Appendices A and B contact management recommendations align with these PHAC recommendations. To inform timely public health management (i.e., to determine whether to recommend chemoprophylaxis for eligible close contacts), when death occurs in a person with iGAS, public health units may need to determine whether or not GAS infection was a contributing cause of death. The case is classified as severe if iGAS is determined to be one of the causes of death.

The PHAC, U.S., Irish, Australian and U.K. management guidelines do not specify a time frame for attributing cause of death to GAS after GAS isolation. For surveillance purposes only (and not to inform management), the U.K. has used 7 days after collection of a positive culture specimen as the time frame for identifying iGAS disease as the cause of death (personal communication; unreferenced, Dr. Theresa Lamagni, November 2011).

It is conceivable that someone may die from complications of an iGAS infection 14, 21, or even 30 days after infection, but there is evidence from a prospective, population-based surveillance study in Ontario that the risk of death related to iGAS is highest in the first 7 days of infection. In addition, an analysis of enhanced surveillance data from the UK in 2003-2004 found that death occurred within the first 7 days after specimen collection in 559 of 698 case-patients with severe S. pyogenes infections who died up to 30 days after collection of a culture-positive specimen. In general, the clinician most responsible for a patient is likely to be in the best position to determine the patient’s contributing cause(s) of death; this likely also applies when death occurs in a patient with iGAS. However, public health units have found it difficult and time-consuming to determine whether iGAS was a contributing cause.
cause of death, as clinicians have either not commented, or were unable to state with certainty whether or not GAS was a contributing cause of death.

Beyond 7 days after the death of a patient with iGAS, in most cases there is very little benefit derived from determining iGAS as a cause of death; chemoprophylaxis is recommended for close contacts for only up to 7 days following last contact with a severe iGAS case.\(^3\)

**Additional comments**

Should a person with iGAS die more than 7 days after diagnosis, public health contact management should remain similar to that for follow-up of contacts of a non-severe case (i.e., all contacts of cases should still be advised to monitor themselves for signs and symptoms of iGAS for 30 days after the date of last exposure to the case [see recommendation 5]). This recommendation does not affect the clinical death certification and other requirements for determining cause of death.

### 2. Utility of pneumonia as a sole indicator of severity

**Recommendation**

For the purpose of public health management of iGAS disease, GAS pneumonia should not be used as a sole indicator of severity.

**Background**

The definition of a severe iGAS case from the PHAC guidelines includes a case of GAS pneumonia (see Appendix 5); the PHAC guidelines also recommend chemoprophylaxis of close contacts of a severe iGAS case.\(^3\) The iGAS disease-specific chapter of the *Ontario Public Health Standards Infectious Diseases Protocol* Appendices A and B case definitions and contact management recommendations align with the PHAC recommendations.\(^1,2\) Like the PHAC guidelines, the U.S., U.K. and Irish guidelines include pneumonia as a sole indicator of invasive disease for the purposes of public health management.\(^4,5,7\)

Pneumonia has been identified as a common presentation of iGAS; for example, 11 per cent of iGAS cases presented with pneumonia in a prospective, population-based study in Ontario.\(^9\) Field experience indicates that attributing pneumonia to GAS infection in a timely fashion (i.e., within 7 days in order to inform chemoprophylaxis recommendations) is a challenge. In the absence of microbiological confirmation from an appropriate respiratory sample, the determination of whether or not the pneumonia is caused by GAS rests with the clinician. The clinical diagnosis of GAS pneumonia is limited with respect to sensitivity and specificity, given that it is based largely on patient signs and symptoms and interpretation of chest x-rays. The challenges and complexity of attributing pneumonia to a causative organism in the context of managing community-acquired pneumonia have been well described.\(^10,11\) PIDAC-CD acknowledges the difficulty of diagnosing pneumonia in iGAS cases, and that severe iGAS cases with pneumonia would most likely have other evidence of severity to meet the case definition for severe iGAS (e.g., streptococcal toxic shock syndrome [STSS]). See Appendix 5 for case definitions.

PIDAC-CD’s recommendation regarding the utility of pneumonia as a sole indicator of clinical severity was made in consultation with Dr. Allison McGeer (personal communication; unreferenced, January 2012).
3. Definition of soft-tissue necrosis as an indicator of severity

**Recommendation**

For the purpose of public health management of iGAS disease, the definition of soft-tissue necrosis should not include superficial or chronic soft-tissue necrosis/gangrene, or acute or chronic cellulitis. Soft-tissue necrosis should be acute in nature and deeper than the skin (e.g., necrotizing fasciitis, myositis and gangrene), as determined by the clinician.

**Background**

Health units have requested clarification about what conditions would meet the definition of soft-tissue necrosis as an indicator of severity in iGAS cases. Necrotizing soft-tissue infection typically presents with sudden onset of intense pain. Necrotizing infections of the skin and soft tissue caused by GAS typically progress rapidly along the fascial planes, resulting in necrosis of subcutaneous tissue. This does not include chronic gangrene or superficial infection, such as cellulitis and infected abscesses.

The PHAC guidelines state that an iGAS case with “soft-tissue necrosis (including necrotizing fasciitis, myositis and gangrene)” is considered to be severe, and would trigger chemoprophylaxis recommendations for eligible close contacts. The iGAS disease-specific chapter of the *Ontario Public Health Standards Infectious Diseases Protocol* Appendices A and B case definitions and contact management recommendations align with the PHAC recommendations.

**Contact Management**

4. Definition of close contacts

**Recommendation**

The Public Health Agency of Canada guidelines’ definition of close contacts should be used to identify groups eligible for chemoprophylaxis, i.e., persons exposed to a confirmed severe iGAS case in the 7 days prior to onset of symptoms in the case or up to 24 hours after the case’s initiation of antimicrobial therapy and who:

- Spent 4 hours/day on average in the previous 7 days, OR 20 hours/week with the case, or
- Shared the same bed or had sexual relations with the case, or
- Had direct mucous membrane contact with oral or nasal secretions of the case or unprotected direct contact with an open skin lesion of the case, or
- Shared needles (i.e., for injection drug use) with the case, or
- In certain circumstances, selected child care and hospital contacts.

If numerous groups of people are identified as eligible for chemoprophylaxis, public health practitioners could give first priority to the timely administration of antibiotic prophylaxis to close contacts in high-risk groups as outlined in the U.S. Centers for Disease Control and Prevention iGAS management guideline (e.g., persons over 65 years, or with HIV infection, diabetes, chickenpox, cancer, heart disease, injection drug or steroid use).
Background

**PHAC guidelines**

The current PHAC guidelines recommend chemoprophylaxis for close contacts of severe iGAS cases. The PHAC guidelines' definition of close contacts (see Appendix 4 and 5) is used to inform contact management, including identification of groups eligible for chemoprophylaxis.

The efficacy and optimal regimen of antibiotic prophylaxis for contacts has not been well established, but the PHAC guidelines currently advise that chemoprophylaxis be offered to close contacts of a case of iGAS with evidence of severity, such as STSS, necrotizing fasciitis, meningitis or death. The purpose of prophylaxis is to eradicate nasopharyngeal colonization of GAS and prevent disease.

**Comparison of guidelines**

The PHAC guidelines differ from the U.S., U.K., Irish and Australian iGAS public health management guidelines (refer to Appendix 1), highlighting the differences in recommendations for chemoprophylaxis that can be developed from similar evidence (see below). Different jurisdictions have followed different lines of reasoning in the development of their guidelines. The 2002 U.S. guidelines are directed at the host factors influencing susceptibility to iGAS disease, whereas the Canadian guidelines attempt to target the bacteria and its virulence with antibiotic use. The relative importance of infection associated with host factors versus infection associated with GAS strain is unknown; this leads to uncertainty in determining the most effective approach to preventing infection.

**Evidence of risk of iGAS disease in contacts from population-based studies**

Two North American prospective, population-based surveillance studies have quantified the risk of iGAS disease among household contacts. Davies et al estimated the rate of iGAS in identified household contacts via active surveillance in the Ontario population. Over the study period (January 1992 to June 1995), four cases occurred in a total of 1,360 household contacts of sporadic iGAS cases. Three household cases occurred in husband and wife pairs, and one case between adult siblings. These observations translate to a rate of 294 cases per 100,000 (95 per cent confidence interval 80–750 cases per 100,000) over the 3.5 year study period.

Robinson et al estimated the risk of iGAS transmission among household contacts in the United States. Over the course of the study period (January 1997 to April 1999), one confirmed case in 1,514 household contacts was reported: a husband-wife pair. A second child–parent probable case pair was also reported, but laboratory confirmation was not made. These data translate to a rate of iGAS among close household contacts of 66 per 100,000 using only laboratory-confirmed cases, or 132.1 per 100,000 using both laboratory-confirmed and probable cases.

In addition, a follow up study using enhanced surveillance from England, Wales and Northern Ireland in 2003 identified five household clusters of iGAS: three mother-neonate pairs and two husband and wife pairs. The risk of further cases in mother or baby was therefore estimated to be high when iGAS occurs in mother or baby in the neonatal period. Using these U.K. data, the number needed to treat (i.e., to receive chemoprophylaxis) to prevent one iGAS case among other household contacts was over 2,000 persons, assuming that chemoprophylaxis was 100 per cent effective.

**Assessment of evidence base for existing guideline recommendations**

There is no strong scientific evidence to quantify the risk of iGAS disease among household contacts of cases. In the PHAC guidelines, the targeted chemoprophylaxis of close contacts linked to severe iGAS cases is based on expert opinion and biological plausibility. Consistency between a particular strain and severity of infection has been observed for other infectious agents, but not for iGAS. The broader
definition of close contacts in the PHAC guidelines relative to other jurisdictions—in particular, the inclusion of those with direct mucous membrane contact with the oral/nasal secretions of a case, and those having sexual contact with or having shared a bed with a case—are also based on expert opinion and biological plausibility. There are no observational studies or case reports documenting transmission of GAS after this type of contact.

Given that only expert opinion is available to explain the differences between guidelines, PIDAC-CD suggests that the PHAC guidelines are appropriate in the Ontario context.

PIDAC-CD also recognizes that some iGAS case and contact investigations have unique and challenging circumstances, logistics and epidemiology, and may require clinical judgment to identify close contacts that should be considered for chemoprophylaxis. While guidelines may provide a point of reference, they are not meant to be a substitute for good judgment on the part of clinicians and public health authorities. The interpretation of guidelines may at times differ from one practitioner to the next.

It is not expected that the application of clinician/public health authority judgment will result in a decision to administer chemoprophylaxis to anyone who would not be routinely included as a close contact in accordance with the PHAC guidelines. It is also anticipated that difficult decisions will have to be made by clinicians and public health authorities in defining the close contacts of a particular iGAS case, especially when the extent of direct mucous membrane contact cannot be well established.

Regardless, all close contacts should routinely receive education on the signs and symptoms of iGAS and be advised to seek medical care should symptoms develop. Emphasis on this standard practice should not be lost as public health practitioners devote efforts to identifying groups eligible for chemoprophylaxis.

5. Duration of monitoring of close contacts of an iGAS case for signs and symptoms of GAS infection: 21 versus 30 days

Recommendation

Public health units’ advice to close contacts on monitoring for signs and symptoms of iGAS should be consistent with the PHAC guidelines’ recommendation to “seek medical attention immediately should they develop febrile illness or any other clinical manifestation of GAS infection within 30 days of diagnosis in the index case”. 3,p.4

Background

The Ministry of Health and Long-Term Care Ontario Public Health Standards Infectious Diseases Protocol, 2013, Group A Streptococcal Disease, Invasive (iGAS) chapter states, “all close contacts of invasive disease should be instructed about the signs and symptoms of GAS infection and advised to seek medical attention if they develop within 30 days after exposure to case.” 1,p.6 This is based on the PHAC guidelines, 3 which are in line with the U.S., U.K. and Irish management guidelines. 4,5,7

There is limited evidence to accurately determine the time it may take for an exposed individual to develop signs and symptoms of GAS. 3 Most secondary cases should occur well before 30 days, but the 30-day duration covers the time that an exposed individual is most likely to present with signs and symptoms of infection. According to Heymann, the incubation period for GAS is 1 to 3 days; 17 however, it is thought that in a person who is colonized with GAS it may take longer (7 to 14 days) 3 for the GAS to
become invasive and symptoms to present (personal communication; unreferenced, Dr. Allison McGeer, August 2012). Recommending that contacts self-monitor for signs and symptoms for 30 days simplifies communications and provides an extra few days as a precaution.

**Screening in Long-Term Care Facilities**

**6. Indications for screening in long-term care facilities for GAS**

**Recommendation**

Public health units and health care providers should follow the PHAC guideline for screening in long-term care facilities (LTCFs) for GAS to avoid unnecessary screening/rescreening.³

As per the PHAC guidelines,³ if a confirmed case of invasive GAS disease is identified in a LTCF, conduct a retrospective chart review to identify an excess of confirmed or suggested GAS among residents in the preceding 4 to 6 weeks. If an excess of GAS infection is identified, consider screening for GAS (i.e., throat, nose and skin lesion cultures) in:

- All patient care staff, and
- All residents in LTCF with < 100 beds, OR, residents in the same unit as the iGAS case and contacts of that case if necessary in LTCF with ≥ 100 beds, OR residents in the same case unit as the iGAS case and contacts of that case if necessary, OR more broadly as suggested by resident or staff movements or epidemiologic evidence.

The PHAC guidelines³, p.4 defines an excess of GAS infection in a LTCF as:

- > 1 case of culture-confirmed iGAS per 100 residents per month, or
- ≥ 2 cases of culture-confirmed iGAS per month in facilities with <200 residents, or
- > 4 cases of suggested invasive or non-invasive GAS per 100 residents per month.

**Background**

Regarding screening in LTCFs, the PHAC guidelines state the following, which apply (as stated below) in a LTCF in which there is a confirmed case of invasive GAS disease:

- When a confirmed case of invasive GAS disease ... occurs in a LTCF such as a nursing home, the facility should [...] conduct a retrospective chart review of the entire facility’s residents over the previous 4 to 6 weeks for culture-confirmed cases of GAS disease and any suggested cases of non-invasive or invasive GAS infection, including skin and soft tissue infections (e.g., pharyngitis and cellulitis) and excluding pneumonia and conjunctivitis not confirmed by culture.³

An excess of GAS infection or a LTCF outbreak is defined by the PHAC guidelines as follows:

- An incidence rate of culture-confirmed invasive GAS infections of > 1 per 100 residents per month or at least two cases of culture-confirmed invasive GAS infection in 1 month in facilities with fewer than 200 residents or an incidence rate of suggested invasive or non-invasive GAS infections of > 4 per 100 residents per month.³, p.4
Subsequently, the PHAC guidelines suggest the following action if an excess of GAS infection is identified:

- All patient care staff should be screened for GAS with throat, nose and skin lesion cultures. In LTCF with < 100 beds, all residents should be screened for GAS. In LTCF with 100 beds or greater, screening can be limited to all residents within the same care unit as the infected case and contacts of the case if necessary, unless patient and care staff movement patterns or epidemiologic evidence (e.g., from the chart review) suggest that screening should be conducted more broadly.\(^3\), p.7

The literature review revealed that the PHAC guidelines on screening for asymptomatic carriers in an iGAS outbreak are not consistent with those of other jurisdictions. For example, both the Irish and the U.K. guidelines do not explicitly recommend screening; instead, they recommend testing and treating those who may become symptomatic with potential GAS pharyngitis or skin infections during the outbreak.\(^5\), \(^7\) PIDAC-CD carefully considered the more liberal PHAC screening recommendations, including their cost-effectiveness, and concluded that there was an absence of strong or convincing evidence for a particular screening approach. The different approaches are largely based on expert opinion and biological plausibility, rather than on strong scientific evidence. Public Health Ontario will continue to analyze local surveillance data on recent iGAS LTCF outbreaks in an attempt to better inform current guidelines.
## Appendices

### Appendix 1: Jurisdictional comparison of recommendations for chemoprophylaxis

<table>
<thead>
<tr>
<th>Jurisdiction</th>
<th>Recommendation for chemoprophylaxis</th>
</tr>
</thead>
</table>
| Australia (Queensland)\(^6\)    | • Communicable disease control manual\(^6\)  
  • Public Health Units may initiate mass antibiotic prophylaxis of children aged 2 to 12 years to control acute post-streptococcal glomerulonephritis outbreaks                                                                 |
| Australia (Victoria)\(^15\)     | • Department of Health, Victoria, Australia,\(^15\) control of contacts:  
  • Consider the diagnosis in symptomatic contacts; few people who come in contact with GAS will develop invasive GAS disease. At present the role of antibiotic prophylaxis for close contacts of cases of invasive GAS infection is uncertain;  
  • However, in certain circumstances, antibiotic therapy may be appropriate for those at higher risk of infection                                                                                             |
| Canada\(^3\)                    | • Chemoprophylaxis is recommended for all close contacts of severe iGAS cases                                                                                                                                                    |
| Ireland\(^5\)                   | • Chemoprophylaxis should be administered to close contacts if they have symptoms suggestive of localized GAS infection; mother and baby if either develops iGAS in the neonatal period (first 28 days of life)                                             |
| United Kingdom\(^7\)            | • Antibiotic prophylaxis should be given only to the following: mother and neonate if either develops iGAS; close contacts if they develop symptoms of strep A infection (e.g., sore throat, fever, skin infection); all household contacts if more than one iGAS case occurs in a household within a 30-day period |
| United States\(^4\)             | • May be given to all household contacts where a member has one of the following risk factors: over 65 years, HIV infection, diabetes, chickenpox, cancer, heart disease, injection drug use, steroid use.                                                 |
### Appendix 2: Jurisdictional comparison of management guidance related to iGAS and death

<table>
<thead>
<tr>
<th>Jurisdiction</th>
<th>Attribution of cause of death to GAS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Australia (Queensland and Victoria)(^6,15)</td>
<td>Not addressed</td>
</tr>
<tr>
<td>Canada(^3)</td>
<td>Not addressed; no time frame specified after Group A Streptococcal (GAS) isolation</td>
</tr>
<tr>
<td>Ireland(^5)</td>
<td>Not addressed</td>
</tr>
<tr>
<td>United Kingdom(^7)</td>
<td>Not addressed</td>
</tr>
<tr>
<td>United States(^4)</td>
<td>Not addressed; no time frame specified after GAS isolation</td>
</tr>
</tbody>
</table>
## Appendix 3: Jurisdictional comparison of guidance related to iGAS and pneumonia

<table>
<thead>
<tr>
<th>Jurisdiction</th>
<th>Reference to pneumonia</th>
<th>Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Australia (Queensland, Victoria)</td>
<td>• Not addressed</td>
<td>No national guidance on invasive GAS</td>
</tr>
<tr>
<td>Canada</td>
<td>• Group A Streptococcal pneumonia specified in definition of severe case (p. 3, Table 2)</td>
<td>Under infection-control measures to prevent transmission of invasive GAS in health care institutions: “For the purpose of infection control, GAS pneumonia with or without a positive blood culture is considered an invasive infection, although not identified as such for reporting” (p. 22)</td>
</tr>
<tr>
<td>Ireland</td>
<td>• Other causes of invasive GAS, including focal infection, autoimmune disease and malignancy.</td>
<td>Document represents expert opinion of iGAS subcommittee, following a review of the scientific literature and a consultation exercise. Clinical component of case definition (current as of January 1, 2004) includes an acute febrile illness that may be associated with streptococcal toxic shock syndrome (p. 6)</td>
</tr>
<tr>
<td>United Kingdom</td>
<td>• Includes pneumonia as part of definition, under “other invasive disease”</td>
<td>Three clinical syndromes are described. The third covers “infections characterized by the isolation of GAS from a normally sterile site in patients not meeting the criteria for streptococcal toxic shock syndrome or necrotizing fasciitis. Included in this group are bacteremia with no identified focus and focal infections such as meningitis, pneumonia…” close contacts, (p. 355)</td>
</tr>
<tr>
<td>United States</td>
<td>• Invasive Group A Streptococcal infections may manifest as any of several clinical syndromes, including pneumonia or bacteremia in association with cutaneous infection</td>
<td>As per CDC case definition (p. 32)</td>
</tr>
</tbody>
</table>
## Appendix 4: Jurisdictional comparison of the definition of close contacts

<table>
<thead>
<tr>
<th>Jurisdiction</th>
<th>Definition of close contact</th>
</tr>
</thead>
<tbody>
<tr>
<td>Australia (Queensland, Victoria)</td>
<td>Not defined</td>
</tr>
</tbody>
</table>
| Canada                           | • Those spending 4 hours per day on average in the previous 7 days or 20 hours per week with the case  
   • Those with the following types of contact with the iGAS case: sharing the same bed, sexual relations, direct mucous membrane contact with oral or nasal secretions of an iGAS case or direct contact with the open skin lesion, shared needles |
| Ireland                          | Household contacts:  
   • All contacts living in the same household as a case of iGAS within the 7 days prior to the case patient becoming ill  
   Other close contacts:  
   • Persons who share sleeping arrangements  
   OR  
   • Persons who have had direct mucous membrane contact with the oral or nasal secretions of a case within 7 days prior to case patient illness |
| United Kingdom                   | • Someone who has had prolonged close contact with a case in a household-type setting during the 7 days prior to the onset of illness |
| United States                    | • Those spending at least 24 hours with the index case in the 7 days prior to the onset of the case patient’s symptoms |
Appendix 5: iGAS case definitions from the PHAC guidelines

Below are the PHAC iGAS definitions for confirmed case, severe case and close contact discussed in the supplement Guidelines for the Prevention and Control of Invasive Group A Streptococcal Disease (p. 3. Table 1), available at http://www.phac-aspc.gc.ca/publicat/ccdr-rmtc/06vol32/32s2/index-eng.php. These definitions are of importance to the queries from public health units:

- **Confirmed case:** Laboratory confirmation of infection, with or without clinical evidence of invasive disease. Laboratory confirmation requires the isolation of group A streptococcus (Streptococcus pyogenes) from a normally sterile site.

- **Severe [iGAS] case:** Case of STSS [streptococcal toxic shock syndrome], soft-tissue necrosis (including necrotizing fasciitis, myositis or gangrene), meningitis, GAS pneumonia, other life-threatening conditions or a confirmed case resulting in death.

- **Close contact:** In order to be considered a close contact, there must have been exposure to the case during the period from 7 days prior to the onset of symptoms in the case to 24 hours after the case’s initiation of antimicrobial therapy.
  - Household contacts of a case who have spent at least 4 hours/day on average in the previous 7 days or 20 hours/week with the case
  - Non-household persons who share the same bed with the case or had sexual relations with the case
  - Persons who have had direct mucous membrane contact with the oral or nasal secretions of a case (e.g., mouth-to-mouth resuscitation, open-mouth kissing) or unprotected direct contact with an open skin lesion of the case
  - Injection drug users who have shared needles with the case
  - Selected LTCF contacts (see Section 6.3 of the PHAC guidelines)
  - Selected child care contacts (see Section 6.4 of the PHAC guidelines)
  - Selected hospital contacts (see Annex 3 of the PHAC guidelines)

---

\(^a\) Clinical evidence of invasive disease may be manifested as several conditions. These include:

- **STSS**, which is characterized by hypotension (systolic blood pressure ≤ 90 mmHg in adults or < 5th percentile for age in children) and at least two of the following signs:
  - i. renal impairment (creatinine level ≥ 177 μmol/L for adults)
  - ii. coagulopathy (platelet count ≤ 100,000/mm or disseminated intravascular coagulation)
  - iii. liver function abnormality (SGOT [AST], SGPT [ALT] or total bilirubin ≥ 2x upper limit of normal)
  - iv. adult respiratory distress syndrome (ARDS)
  - v. generalized erythematous macular rash that may desquamate

- **b)** soft-tissue necrosis, including necrotizing fasciitis, myositis or gangrene;
- **c)** meningitis; or
- **d)** a combination of the above.
### Appendix 6: Search strategies

**Search Strategies**

iGAS infection and close contacts peer-reviewed literature search

**SEARCH 1:** CINAHL with Full Text, Show all MEDLINE, Academic Search Premier, Nursing & Allied Health Collection: Comprehensive

<table>
<thead>
<tr>
<th>#</th>
<th>Query</th>
</tr>
</thead>
<tbody>
<tr>
<td>S7</td>
<td>(Streptococcus pyogenes or Streptococcus group A or Invasive group A Streptococcus infections) AND intimate contact</td>
</tr>
<tr>
<td>S6</td>
<td>(Streptococcus pyogenes or Streptococcus group A or Invasive group A Streptococcus infections) AND (cross infection or disease transmission)</td>
</tr>
<tr>
<td>S5</td>
<td>(Streptococcus pyogenes or Streptococcus group A or Invasive group A Streptococcus infections) AND (cross infection or disease transmission)</td>
</tr>
<tr>
<td>S4</td>
<td>(family or intra-familial or case-patient or “person to person” or shared environment or carriage or familial carriage or “close contact”) AND (Streptococcus pyogenes or Streptococcus group A or Invasive group A Streptococcus infections) AND (cross infection or disease transmission)</td>
</tr>
<tr>
<td>S3</td>
<td>(STREPTOCOCCUS pyogenes OR STREPTOCOCCAL infections) AND (family or intra-familial)</td>
</tr>
<tr>
<td>S2</td>
<td>(STREPTOCOCCUS pyogenes OR STREPTOCOCCAL infections) AND cross</td>
</tr>
<tr>
<td>S1</td>
<td>(STREPTOCOCCUS pyogenes OR STREPTOCOCCAL infections) AND &quot;close contact&quot;</td>
</tr>
</tbody>
</table>

**SEARCH 2:**

<table>
<thead>
<tr>
<th>#</th>
<th>Searches</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Streptococcus pyogenes /</td>
</tr>
<tr>
<td>2</td>
<td>Streptococcus group A/ or group A streptococcal infection/ or Streptococcus infection/ or bacterial infection/</td>
</tr>
<tr>
<td>3</td>
<td>1 or 2</td>
</tr>
<tr>
<td>4</td>
<td>family/</td>
</tr>
<tr>
<td>5</td>
<td>intra-familial.mp.</td>
</tr>
<tr>
<td>6</td>
<td>close contact.mp.</td>
</tr>
<tr>
<td>7</td>
<td>carriage.mp.</td>
</tr>
<tr>
<td>#</td>
<td>Searches</td>
</tr>
<tr>
<td>----</td>
<td>--------------------------------------------------------------------------</td>
</tr>
<tr>
<td>8</td>
<td>shared environment.mp.</td>
</tr>
<tr>
<td>9</td>
<td>person to person.mp.</td>
</tr>
<tr>
<td>10</td>
<td>familial carriage.mp.</td>
</tr>
<tr>
<td>11</td>
<td>intimate contact.mp.</td>
</tr>
<tr>
<td>12</td>
<td>4 or 5 or 6 or 7 or 8 or 9 or 10 or 11</td>
</tr>
<tr>
<td>13</td>
<td>disease transmission/</td>
</tr>
<tr>
<td>14</td>
<td>cross infection/dm, ep, pc [Disease Management, Epidemiology, Prevention]</td>
</tr>
<tr>
<td>15</td>
<td>13 or 14</td>
</tr>
<tr>
<td>16</td>
<td>3 and 12 and 15</td>
</tr>
<tr>
<td>17</td>
<td>limit 16 to (english language and yr=&quot;2008 -Current&quot;)</td>
</tr>
<tr>
<td>18</td>
<td>3 and 15</td>
</tr>
<tr>
<td>19</td>
<td>limit 18 to (human and english language and yr=&quot;2008 -Current&quot;)</td>
</tr>
<tr>
<td>20</td>
<td>1 and 15</td>
</tr>
<tr>
<td>21</td>
<td>limit 20 to (english language and yr=&quot;2008 -Current&quot;)</td>
</tr>
<tr>
<td>22</td>
<td>Streptococcus group A/ 3468</td>
</tr>
<tr>
<td>23</td>
<td>15 and 22</td>
</tr>
<tr>
<td>24</td>
<td>limit 23 to (english language and yr=&quot;2008 -Current&quot;)</td>
</tr>
<tr>
<td>25</td>
<td>17 or 21 or 24</td>
</tr>
</tbody>
</table>
iGAS infection and definition of close contacts web/grey literature search

APIC Text: http://text.apic.org/item-75/chapter-71-streptococci/basic-principles

CANADA


UNITED KINGDOM


UNITED STATES OF AMERICA


AUSTRALIA

## iGAS guidelines peer-reviewed literature search

### iGAS guidelines 1998-current (EMBASE)

**SEARCH 1:**

<table>
<thead>
<tr>
<th>#</th>
<th>Searches</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>iGAS.mp.</td>
</tr>
<tr>
<td>2</td>
<td>exp Streptococcus/</td>
</tr>
<tr>
<td>3</td>
<td>exp Streptococcal Infections/</td>
</tr>
<tr>
<td>4</td>
<td>streptococcal disease.mp</td>
</tr>
<tr>
<td>5</td>
<td>group A.mp.</td>
</tr>
<tr>
<td>6</td>
<td>2 or 3 or 4</td>
</tr>
<tr>
<td>7</td>
<td>5 and 6</td>
</tr>
<tr>
<td>8</td>
<td>invasive group A streptococ*.mp.</td>
</tr>
<tr>
<td>9</td>
<td>1 or 8</td>
</tr>
<tr>
<td>10</td>
<td>(guideline* or recommend*).mp.</td>
</tr>
<tr>
<td>11</td>
<td>9 and 10</td>
</tr>
<tr>
<td>12</td>
<td>7 and 10</td>
</tr>
<tr>
<td>13</td>
<td>11 or 12</td>
</tr>
<tr>
<td>14</td>
<td>limit 13 to yr=&quot;1998 -Current&quot;</td>
</tr>
<tr>
<td>15</td>
<td>from 14 keep 10, 12, 16, 18, 25, 28...</td>
</tr>
</tbody>
</table>

### iGAS Guidelines – 1998-current (MEDLINE)

**SEARCH 2:**

<table>
<thead>
<tr>
<th>#</th>
<th>Searches</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>iGAS.mp.</td>
</tr>
<tr>
<td>2</td>
<td>exp Streptococcus/</td>
</tr>
<tr>
<td>3</td>
<td>exp Streptococcal Infections/</td>
</tr>
<tr>
<td>4</td>
<td>group A.mp.</td>
</tr>
<tr>
<td>5</td>
<td>invasive group A streptococ*.mp.</td>
</tr>
<tr>
<td>6</td>
<td>2 or 3</td>
</tr>
<tr>
<td>7</td>
<td>4 and 6</td>
</tr>
<tr>
<td>8</td>
<td>1 or 5</td>
</tr>
<tr>
<td>9</td>
<td>(guideline* or recommend*).mp.</td>
</tr>
<tr>
<td>10</td>
<td>8 and 9</td>
</tr>
<tr>
<td>11</td>
<td>7 and 9</td>
</tr>
<tr>
<td>12</td>
<td>10 or 11</td>
</tr>
<tr>
<td>13</td>
<td>from 12 keep 2-3, 5-6, 9, 14-15, 21, 27...</td>
</tr>
</tbody>
</table>
iGAS guidelines grey literature (Google)

Invasive group A streptococcus guidelines

Search strategy: A web search was performed using Google to identify grey literature regarding guidelines relating to invasive group A streptococcus. The websites of major public health agencies were the focus of the search, such as www.phac-aspc.gc.ca and www.cdc.gov. The websites of all Canadian provincial and territorial health ministries were searched, as well as those of international and national organizations (see below for a list of websites searched). Additionally, a Google search was performed, limiting the results to .gov, .org., and .edu domains. References in highly relevant results were also examined.

Relevant results:

INTERNATIONAL


CANADA

Alberta:

British Columbia:

Manitoba:

Newfoundland and Labrador:
Northwest Territories:

Ontario:


Québec:


Saskatchewan:
UNITED KINGDOM


UNITED STATES OF AMERICA:


U.S. states and municipalities:


Website checklist: Infectious diseases

☑ www.phac-aspc.gc.ca
☑ www.msss.gouv.qc.ca
☑ www.hc-sc.gc.ca
☑ www.inspq.qc.ca
☑ health-evidence.ca/
☑ www.gnb.ca/0051/index-e.asp
☑ www.cps.ca
☑ www.gov.ns.ca/DHW
☑ www.cma.ca
☑ www.gov.pe.ca/health
☑ www.gov.bc.ca/health
☑ www.health.gov.nl.ca
☑ www.healthlinkbc.ca
☑ www.hss.gov.nu.ca
☑ www.bccdc.ca
☑ www.hlthss.gov.nt.ca
☑ www.health.alberta.ca
☑ www.hss.gov.yk.ca
☑ www.health.gov.sk.ca
☑ www.who.int/
☑ www.gov.mb.ca/health
☑ www.cdc.gov/
☑ www.publichealthontario.ca
☑ www.ecdc.europa.eu/
☑ www.health.gov.on.ca
☑ www.idsociey.org
☑ https://www.oma.org/
☑ www.isid.org/

*Streptococcus pyogenes* and transmission peer review literature

SEARCH 1 - MEDLINE

<table>
<thead>
<tr>
<th>#</th>
<th>Query</th>
<th>Limiters/Expanders</th>
</tr>
</thead>
<tbody>
<tr>
<td>S5</td>
<td>((MH &quot;Disease Transmission, Infectious&quot;) and (S4)) Search modes - Boolean/Phrase</td>
<td></td>
</tr>
<tr>
<td>S4</td>
<td>(MH &quot;Disease Transmission, Infectious&quot;) Search modes - Boolean/Phrase</td>
<td></td>
</tr>
<tr>
<td>S3</td>
<td>( (MH &quot;Infectious Disease Transmission, Professional-to-Patient&quot;) OR (MH &quot;Infectious Disease Transmission, Patient-to-Professional&quot;) OR (MH &quot;Infectious Disease Transmission, Vertical&quot;) OR (MH &quot;Disease Transmission, Infectious&quot;) OR (MH &quot;Cross-Sectional Studies&quot;) ) AND MH &quot;Streptococcus pyogenes&quot; Search modes - Boolean/Phrase</td>
<td></td>
</tr>
<tr>
<td>S2</td>
<td>(MH &quot;Infectious Disease Transmission, Professional-to-Patient&quot;) OR (MH &quot;Infectious Disease Transmission, Patient-to-Professional&quot;) OR (MH &quot;Infectious Disease Transmission, Vertical&quot;) OR (MH &quot;Disease Transmission, Infectious&quot;) OR (MH &quot;Cross-Sectional Studies&quot;) Search modes - Boolean/Phrase</td>
<td></td>
</tr>
<tr>
<td>#</td>
<td>Query</td>
<td>Limiters/Expanders</td>
</tr>
<tr>
<td>----</td>
<td>----------------------------------------------------------------------</td>
<td>------------------------------------</td>
</tr>
<tr>
<td>S1</td>
<td>(MM &quot;Streptococcus pyogenes&quot;)</td>
<td>Search modes - Boolean/Phrase</td>
</tr>
</tbody>
</table>

**SEARCH 2 - EMBASE**

<table>
<thead>
<tr>
<th>#</th>
<th>Searches</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>exp disease transmission/pc [Prevention]</td>
</tr>
<tr>
<td>2</td>
<td>Staphylococcus infection/ or bacterial transmission/ or hospital infection/ or cross infection/or infection control/</td>
</tr>
<tr>
<td>3</td>
<td>Streptococcus pyogenes/</td>
</tr>
<tr>
<td>4</td>
<td>Streptococcus group A/</td>
</tr>
<tr>
<td>5</td>
<td>bacterial transmission/ or hospital infection/ or cross infection/ or infection control/</td>
</tr>
<tr>
<td>6</td>
<td>3 or 4</td>
</tr>
<tr>
<td>7</td>
<td>1 or 5</td>
</tr>
<tr>
<td>8</td>
<td>6 and 7</td>
</tr>
<tr>
<td>9</td>
<td>limit 8 to (english language and yr=&quot;2002 - Current&quot;)</td>
</tr>
<tr>
<td>10</td>
<td>from 9 keep 1-2, 4, 6, 18, 22, 32-33...</td>
</tr>
</tbody>
</table>

**iGAS outbreaks in hospitals/long-term care facilities peer reviewed literature**

**SEARCH - MEDLINE**

Ovid MEDLINE(R) In-Process & Other Non-Indexed Citations and Ovid MEDLINE(R) 1946 to Present

<table>
<thead>
<tr>
<th>#</th>
<th>Searches</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>outbreak*.mp.</td>
</tr>
<tr>
<td>2</td>
<td>Streptococcus group A/</td>
</tr>
<tr>
<td>3</td>
<td>Streptococcus pyogenes/</td>
</tr>
<tr>
<td>4</td>
<td>long term care/</td>
</tr>
<tr>
<td>#</td>
<td>Searches</td>
</tr>
<tr>
<td>----</td>
<td>-----------------------------------------------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>5</td>
<td>health care facility/</td>
</tr>
<tr>
<td>6</td>
<td>hospital/</td>
</tr>
<tr>
<td>7</td>
<td>Streptococcus infection/ or Streptococcus pneumoniae/ or bacteremia/ or Streptococcus Health Facilities/</td>
</tr>
<tr>
<td>8</td>
<td>disease outbreaks.mp. [mp=ti, ab, sh, hw, tn, ot, dm, mf, dv, kw, nm, ps, rs, ui]</td>
</tr>
<tr>
<td>9</td>
<td>Streptococcal Infections.mp. [mp=ti, ab, sh, hw, tn, ot, dm, mf, dv, kw, nm, ps, rs, ui]</td>
</tr>
<tr>
<td>10</td>
<td>*Streptococcus infection/et [Etiology]</td>
</tr>
<tr>
<td>11</td>
<td>*Streptococcus group A/</td>
</tr>
<tr>
<td>12</td>
<td>*long term acute care hospital/</td>
</tr>
<tr>
<td>13</td>
<td>disease transmission.mp. [mp=ti, ab, sh, hw, tn, ot, dm, mf, dv, kw, nm, ps, rs, ui]</td>
</tr>
<tr>
<td>14</td>
<td>2 or 3 or 10 or 11 or 12</td>
</tr>
<tr>
<td>15</td>
<td>hospital infection/</td>
</tr>
<tr>
<td>16</td>
<td>4 or 5 or 6 or 8 or 13</td>
</tr>
<tr>
<td>17</td>
<td>9 or 16</td>
</tr>
<tr>
<td>18</td>
<td>1 and 15 and 17 and 18</td>
</tr>
</tbody>
</table>
References


